Gilead (GILD) Received FDA Orphan Drug Designation for Treatment to Prevent Mother to Child Transmission of Hepatitis B Virus.
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Gilead Sciences' (NASDAQ: GILD) tenofovir disoproxil fumarate was granted an Orphan Drug Designation for prevention of mother to child transmission of hepatitis B virus.
|Generic Name:||tenofovir disoproxil fumarate|
|Orphan Designation:||Prevention of mother to child transmission of hepatitis B virus|
|Orphan Designation Status:||Designated|
|FDA Orphan Approval Status:||Not FDA Approved for Orphan Indication|
|Marketing Approval Date:||N/A|
|Approved Labeled Indication:|
|Exclusivity End Date:||N/A|
|Sponsor:||Gilead Sciences, Inc.|
333 Lakeside Drive
Foster City, California 94404
The sponsor address listed is the last reported by the sponsor to OOPD.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Announces Results from Studies of Switching HIV-1 Patients to Descovy; Results Statistically non-Inferior
- Gilead Sciences (GILD) Announces Tipline Data from Four Sofosbuvir , Velpatasvir, Voxilaprevir Phase 3s in Genotype 1 - 6 HCV
- Windtree Therapeutics (WINT) Releases Data from Lung Deposition Study Conducted in Non-Human Primates
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!